From: A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients
Tumor Response as per RECIST v1.1
Arm A, N = 3
Arm B, N = 5
Number of patients
CR
0
PR
SD
1
2
PD
3